In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae

被引：25
|
作者：
Welsh, L
Gaydos, C
Quinn, TC
机构：
[1] JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205
[2] NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1996年 / 40卷 / 01期
关键词：
D O I：
10.1128/AAC.40.1.212
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Thirteen strains of Chlamydia pneumoniae were evaluated for their in vitro susceptibilities to azithromycin, clarithromycin, erythromycin, and tetracycline. The MIC ranges were 0.125 to 0.5 mu g/ml for azithromycin, 0.031 to 1.0 mu g/ml for clarithromycin, 0.125 to 1.0 mu g/ml for erythromycin, and 0.125 to 1.0 mu g/ml for tetracycline, The ranges for the minimal lethal concentrations were 0.125 to 0.5 mu g/ml for azithromycin. 0.031 to 1.0 mu g/ml for clarithromycin, 0.125 to 1.0 mu g/ml for erythromycin, and 0.25 to 1.0 mu g/ml for tetracycline. Clarithromycin and azithromycin were the most active antibiotics against C. pneumoniae in vitro.
引用
收藏
页码：212 / 214
页数：3
相关论文
共 50 条
  • [31] In Vitro Activity of Omadacycline against Chlamydia pneumoniae
    Kohlhoff, Stephan A.
    Huerta, Natalia
    Hammerschlag, Margaret R.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (02)
  • [32] In vitro activity of trovafloxacin against Chlamydia pneumoniae
    Roblin, PM
    Kutlin, A
    Hammerschlag, MR
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (09) : 2033 - 2034
  • [33] In Vitro Synergy Between Ranitidine Bismuth Citrate and Tetracycline or Clarithromycin Against Resistant Strains of Helicobacter pylori
    P. D. Midolo
    J. R. Lambert
    T. G. Kerr
    W. Tee
    [J]. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18 : 832 - 834
  • [34] In vitro synergy between ranitidine bismuth citrate and tetracycline or clarithromycin against resistant strains of Helicobacter pylori
    Midolo, PD
    Lambert, JR
    Kerr, TG
    Tee, W
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (11) : 832 - 834
  • [35] In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA
    Smith, RP
    Baltch, AL
    Ritz, WJ
    Carpenter, AN
    Halse, TA
    Bopp, LH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) : 2081 - 2084
  • [36] Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae
    Kosowska, K
    Credito, K
    Pankuch, GA
    Hoellman, D
    Lin, GR
    Clark, C
    Dewasse, B
    McGhee, P
    Jacobs, MR
    Appelbaum, PC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (11) : 4113 - 4119
  • [37] Phenotypic and molecular characterization of tetracycline- and erythromycin-resistant strains of Streptococcus pneumoniae
    Montanari, MP
    Cochetti, I
    Mingoia, M
    Varaldo, PE
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) : 2236 - 2241
  • [38] In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae
    Roblin, PM
    Hammerschlag, MR
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (04) : 549 - 551
  • [39] In vitro activity of midecamycin diacetate against Mycoplasma pneumoniae and Chlamydia pneumoniae
    Pereyre, S
    de Barbeyrac, B
    Renaudin, H
    Poutiers, F
    Bébéar, C
    Bébéar, CM
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (02) : 240 - 241
  • [40] In vitro activities of doxycycline and enrofloxacin against European Chlamydia psittaci strains from turkeys
    Butaye, P
    Ducatelle, R
    DeBacker, P
    Vermeersch, H
    Remon, JP
    Haesebrouck, F
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (12) : 2800 - 2801
12345